Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

21. Brexpiprazole (Rexulti) - schizophrenia

Brexpiprazole (Rexulti) - schizophrenia Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated to include

Health Canada - Drug and Health Product Register2018

22. Cost-effectiveness of cognitive–behavioural therapy for sleep disorder added to usual care in patients with schizophrenia: the BEST study

Cost-effectiveness of cognitive–behavioural therapy for sleep disorder added to usual care in patients with schizophrenia: the BEST study 29971156 2018 11 14 2056-4724 4 3 2018 May BJPsych open BJPsych Open Cost-effectiveness of cognitive-behavioural therapy for sleep disorder added to usual care in patients with schizophrenia: the BEST study. 126-135 10.1192/bjo.2018.2 Sleep problems are pervasive in people with schizophrenia, but there are no clinical guidelines for their treatment (...) . The Better Sleep Trial (BEST) concluded that suitably adapted cognitive-behavioural therapy (CBT) is likely to be highly effective, although its cost-effectiveness is unknown. To assess the potential cost-effectiveness of CBT for sleep disorders in patients with schizophrenia. An economic evaluation of the BEST study with a 6-month time horizon was used to establish the cost-effectiveness of CBT plus usual care in terms of costs per quality-adjusted life year (QALY) gained. Uncertainty was displayed

BJPsych open2018 Full Text: Link to full Text with Trip Pro

23. Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia

Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia NIHR DC | Signal - Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Published on 14 November 2017 For adults with schizophrenia who continue to have symptoms despite treatment with the antipsychotic drug (...) in these circumstances but does not specify any particular drug. Amisulpride is often used in practice, but to date, there had not been much evidence on which to base this decision. Only 68 people with this severe form of schizophrenia were recruited instead of the expected 230, so the ability to detect any clinically significant differences between the groups is reduced. Share your views on the research. Why was this study needed? About 220,000 people in England and Wales have a diagnosis of schizophrenia. In 2007

NIHR Dissemination Centre2018

24. Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City

Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro- Psychiatric Hospital, Benin City Felicia Ibironke Thomas, Sunday Osasu Olotu and Joyce Ohiole Omoaregba Background Non-attendancetoclinicappointmentsisassociatedwithpoorer treatment outcomes (...) . There is a dearth of information about missed first clinic appointments among patients with schizo- phrenia in Nigeria. Aims Todeterminetheprevalence,correlatesandreasonsformissed first appointment among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City, Nigeria. Method Across-sectionaldescriptivestudyamong275out-patientswith schizophrenia, using the Mini International Neuro-Psychiatric Interview and the Brief Psychiatric Rating Scale. Results The prevalence of missed first

BJPsych open2018 Full Text: Link to full Text with Trip Pro

25. Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics ORIGINAL RESEARCH ARTICLE Economic Impact in Medicaid Bene?ciaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics Marie-He ´le `ne Lafeuille 1 • Neeta Tandon 2 • Sean Tiggelaar 1 • Rhiannon Kamstra 1 • Patrick Lefebvre 1 • Edward Kim (...) 2 • Yong Yue 2 • Kruti Joshi 2 Published online: 23 January 2018 The Author(s) 2018. This article is an open access publication Abstract Objective The objective of this study was to compare persistence, costs, and healthcare resource utilization in patients with schizophrenia and cardiometabolic comor- bidities treated with once-monthly paliperidone palmitate or an oral atypical antipsychotic. Methods Medicaid data from six states (07/2009–03/2015) were used to identify adults

Drugs - real world outcomes2018 Full Text: Link to full Text with Trip Pro

26. Transcranial Magnetic Stimulation for Major Depression and Schizophrenia

Transcranial Magnetic Stimulation for Major Depression and Schizophrenia Transcranial Magnetic Stimulation for Major Depression and Schizophrenia An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017 An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017. This report was prepared by: Ma N, Atukorale Y, Duncan J, Marlow N, Cameron A Research and Evaluation, incorporating ASERNIP-S, Royal (...) www.saxinstitute.org.au knowledge.exchange@saxinstitute.org.au Phone: +61 2 91889500 Suggested Citation: Ma N, Atukorale Y, Marlow N, Duncan J, Cameron A (2017) Transcranial Magnetic Stimulation for major depression and schizophrenia: an Evidence Check brokered by the Sax Institute (www.saxinstitute.org.au) for the NSW Ministry of Health, 2017. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency. It is not necessarily

Sax Institute Evidence Check2018

27. Schizophrenia

Schizophrenia Schizophrenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Schizophrenia Last reviewed: August 2018 Last updated: June 2018 Summary An illness characterised by a co-occurrence of at least two of the following symptoms: hallucinations, delusions, disorganised speech, disorganised/catatonic behaviour, or negative symptoms occurring for a significant period of time during a 1-month period and associated (...) psychosis. Initially, patients are usually referred by family members. As the illness progresses, patients tend to self-refer or are brought in by a case manager or law enforcement officer. Antipsychotic therapy and psychosocial interventions are effective for most patients, but to varying degrees. Suicidal tendency is one of the most dangerous complications. The lifetime risk of suicide is around 5%. The risk is highest at the onset of the illness. Definition Schizophrenia is an illness characterised

BMJ Best Practice2018

28. Zuclopenthixol dihydrochloride for schizophrenia.

Zuclopenthixol dihydrochloride for schizophrenia. BACKGROUND: Oral zuclopenthixol dihydrochloride (Clopixol) is an anti-psychotic treatment for people with psychotic symptoms, especially those with schizophrenia. It is associated with neuroleptic malignant syndrome, a prolongation of the QTc interval, extra-pyramidal reactions, venous thromboembolism and may modify insulin and glucose responses. OBJECTIVES: To determine the effects of zuclopenthixol dihydrochloride for treatment (...) of schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (latest search 09 June 2015). There were no language, date, document type, or publication status limitations for inclusion of records in the register. SELECTION CRITERIA: All randomised controlled trials (RCTs) focusing on zuclopenthixol dihydrochloride for schizophrenia. We included trials meeting our inclusion criteria and reporting useable data. DATA COLLECTION AND ANALYSIS: We extracted data independently

Cochrane2017

29. Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses

Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses 285 Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses Scott Zeller, Leslie Zun, James V. Cassella, Daniel A. Spyker and Paul P . Yeung Background Efficacy of inhaled loxapine 5 or 10 mg in treating agitation was shown using the Positive and Negative Syndrome Scale – Excited Component (PANSS-EC) in two Phase III randomised (...) , double-blind, placebo-controlled trials in 344 agitated patients with schizophrenia and 314 patients with bipolar I disorder (Clinicaltrials.gov: NCT00628589, NCT00721955). Aims To examine the five individual items comprising the PANSS-EC and the percentage of patients achieving a clinical response (reduction of =40%) in PANSS-EC (Response-40) for these two studies. Method Response-40 was examined at the primary end-point (2 h) and over time. Results Response-40 and each PANSS-EC item score were

BJPsych open2017 Full Text: Link to full Text with Trip Pro

30. Individual differences in schizophrenia

Individual differences in schizophrenia 265 Individual differences in schizophrenia Edmund T . Rolls, Wenlian Lu, Lin Wan, Hao Yan, Chuanyue Wang, Fude Yang, Yunlong Tan, Lingjiang Li, Chinese Schizophrenia Collaboration Group, Hao Yu, Peter F . Liddle, Lena Palaniyappan, Dai Zhang, Weihua Yue and Jianfeng Feng Background Whether there are distinct subtypes of schizophrenia is an important issue to advance understanding and treatment of schizophrenia. Aims To understand and treat individuals (...) with schizophrenia, the aim was to advance understanding of differences between individuals, whether there are discrete subtypes, and how first-episode patients (FEP) may differ from multiple episode patients (MEP). Method These issues were analysed in 687 FEP and 1880 MEP with schizophrenia using the Positive and Negative Syndrome Scale for (PANSS) schizophrenia before and after antipsychotic medication for 6 weeks. Results The seven Negative Symptoms were correlated with each other and with P2 (conceptual

BJPsych open2017 Full Text: Link to full Text with Trip Pro

31. Treatment for Adults With Schizophrenia

Treatment for Adults With Schizophrenia Comparative Effectiveness Review Number 198 Treatments for Schizophrenia in Adults: A Systematic Review eComparative Effectiveness Review Number 198 Treatments for Schizophrenia in Adults: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00009-I Prepared by: Pacific Northwest Evidence-based Practice Center (...) Portland, OR Investigators: Marian S. McDonagh, Pharm.D. Tracy Dana, M.L.S. Shelley Selph, M.D., M.P.H. Emily B. Devine, Pharm.D., Ph.D., M.B.A. Amy Cantor, M.D., M.P.H. Christina Bougatsos, M.P.H. Ian Blazina, M.P.H. Sara Grusing, B.A. Rochelle Fu, Ph.D. Sarah L. Kopelovich, Ph.D. Maria Monroe-DeVita, Ph.D. Daniel W. Haupt, M.D. AHRQ Publication No. 17(18)-EHC031-EF October 2017 Key Messages Purpose of Review To evaluate treatments for schizophrenia. Key Messages • Olanzapine, aripiprazole

Effective Health Care Program (AHRQ)2017

32. Morphology of the corpus callosum and schizophrenia: A case-control study in Kashan, Iran

Morphology of the corpus callosum and schizophrenia: A case-control study in Kashan, Iran 29238487 2018 11 13 2008-5842 9 10 2017 Oct Electronic physician Electron Physician Morphology of the corpus callosum and schizophrenia: A case-control study in Kashan, Iran. 5478-5486 10.19082/5478 Corpus Callosum (CC) plays a significant role in hemispheric communication and in lateralized brain function and behaviors. Structural abnormalities in the corpus callosum of schizophrenic patients were (...) reported. However, previous studies regarding the relationship between morphology of CC in patients with schizophrenia and healthy people are controversial. To evaluate the morphological differences of the CC between patients with chronic schizophrenia and healthy people and to examine the relationship between the characteristics of the CC and schizophrenia severity. This cross-sectional study was conducted on 63 patients with chronic schizophrenia (the case group) referred to Kargarnezhad Psychiatric

Electronic physician2017 Full Text: Link to full Text with Trip Pro

33. Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders.

Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. BACKGROUND: Delivering the diagnosis of a serious illness is an important skill in most fields of medicine, including mental health. Research has found that communication skills can impact on a person's recall and understanding of the diagnosis, treatment options and prognosis. People may feel confused and perplexed when information about their illness is not communicated properly. Sharing (...) diagnoses to people; however, little is known specifically for delivering a diagnosis of schizophrenia. OBJECTIVES: To evaluate evidence from randomised controlled trials (RCTs) for the efficacy of different communication strategies used by clinicians to inform people about the diagnosis and outcome of schizophrenia compared with treatment as usual and to compare efficacy between different communication strategies. SEARCH METHODS: On 22 June 2015 and 29 June 2016, we searched the Cochrane Schizophrenia

Cochrane2017

34. A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina

A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina 29623634 2018 11 14 2509-4254 2 3 2018 Sep PharmacoEconomics - open Pharmacoecon Open A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina. 233-239 10.1007/s41669-017-0058-8 Schizophrenia is considered a serious mental disorder that affects over 21 million people worldwide (...) of the butyrophenone group of drugs) versus risperidone [an atypical or second-generation antipsychotic (neuroleptic) drug] in adult patients who have been diagnosed with schizophrenia. To achieve this objective, an exhaustive search of relevant articles published between 2006 and April 2017 was conducted. This literature search showed that intermittent treatment usually fails to prevent relapses due to irregular protection, therefore continuous treatment is more effective. Although the injectable formats of both

PharmacoEconomics open2017 Full Text: Link to full Text with Trip Pro

35. Obesity in individuals with schizophrenia: a case controlled study in Scotland

Obesity in individuals with schizophrenia: a case controlled study in Scotland 29093827 2018 11 13 2056-4724 3 5 2017 Sep BJPsych open BJPsych Open Obesity in individuals with schizophrenia: a case controlled study in Scotland. 254-256 10.1192/bjpo.bp.116.003640 Despite extensive clinical concern about rates of obesity in patients with schizophrenia, there is little evidence of the extent of this problem at a population level. To estimate levels of obesity in a national population sample (...) by comparing patients with schizophrenia with matched controls. We calculated levels of obesity for each patient with schizophrenia from the national Primary Care Clinical Informatics Unit database (n=4658) matched with age, gender and neighbourhood controls. We demonstrated a significant increased obesity hazard for the schizophrenia group using Cox regression analysis, with odds ratio (OR) of 1.94 (95% CI 1.81-2.10) (under the assumption of missing body mass index (BMI) indicating non-obesity

BJPsych open2017 Full Text: Link to full Text with Trip Pro

36. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness

Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page (...) you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} This trial of adding amisulpride in clozapine-unresponsive schizophrenia under-recruited and did not show any statistically significant response at 12 weeks. {{author}} {{($index , , , , , , , , , , , , , , , , & . Thomas RE Barnes 1, 2, * , Verity C Leeson 1

NIHR HTA programme2017

37. Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia

Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia 28750580 2017 07 28 2017 10 10 2017 10 10 1535-7228 174 10 2017 Oct 01 The American journal of psychiatry Am J Psychiatry Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia. 990-998 10.1176/appi.ajp.2017.16091097 This study evaluated rates of all-cause mortality and self-harm in association with clozapine treatment in individuals with treatment-resistant (...) schizophrenia. A population-based cohort of 2,370 individuals with treatment-resistant schizophrenia after Jan. 1, 1996, was followed until death, first episode of self-harm, emigration, or June 1, 2013. Time to all-cause death and time to first episode of self-harm were analyzed in Cox regression models with time-varying treatment, adjusted for clinical and sociodemographic covariates. The rate of all-cause mortality was higher for patients not receiving clozapine than for those given clozapine (hazard

EvidenceUpdates2017

38. Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth

Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth 28764561 2017 08 02 2017 09 09 1497-0015 62 9 2017 Sep Canadian journal of psychiatry. Revue canadienne de psychiatrie Can J Psychiatry Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth. 635-647 10.1177/0706743717720197 Schizophrenia spectrum and other psychotic disorders often have (...) their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes. This article aims to identify best practices in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders. A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders in children

CMA Infobase (Canada)2017 Full Text: Link to full Text with Trip Pro

39. Canadian practice guidelines for comprehensive community treatment for schizophrenia and schizophrenia spectrum disorders

Canadian practice guidelines for comprehensive community treatment for schizophrenia and schizophrenia spectrum disorders 28886669 2017 09 09 2017 09 09 1497-0015 62 9 2017 Sep Canadian journal of psychiatry. Revue canadienne de psychiatrie Can J Psychiatry Canadian Practice Guidelines for Comprehensive Community Treatment for Schizophrenia and Schizophrenia Spectrum Disorders. 662-672 10.1177/0706743717719900 The objective of this review is to identify the features and components (...) of a comprehensive system of services for people living with schizophrenia. A comprehensive system was conceived as one that served the full range of people with schizophrenia and was designed with consideration of the incidence and prevalence of schizophrenia. The system should provide access to the full range of evidence-based services, should be recovery oriented, and should provide patient-centred care. A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum

CMA Infobase (Canada)2017 Full Text: Link to full Text with Trip Pro

40. Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders

Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders 28886671 2017 09 09 2017 09 09 1497-0015 62 9 2017 Sep Canadian journal of psychiatry. Revue canadienne de psychiatrie Can J Psychiatry Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders. 624-634 10.1177/0706743717720196 Persons with schizophrenia and other psychotic disorders frequently have coexisting (...) substance use disorders that require modifications to treatment approaches for best outcomes. The objectives of this review were to identify evidence-based practices best practices that improve outcomes for individuals with schizophrenia and substance used disorders. We reviewed guidelines that were published in the last 5 years and that included systematic reviews or meta-analyses. Most of our recommendations came from 2 publications from the National Institute for Health and Care Excellence (NICE

CMA Infobase (Canada)2017 Full Text: Link to full Text with Trip Pro